Literature DB >> 24727867

Impact of hyperaemic microvascular resistance on fractional flow reserve measurements in patients with stable coronary artery disease: insights from combined stenosis and microvascular resistance assessment.

Tim P van de Hoef1, Froukje Nolte2, Mauro EchavarrÍa-Pinto3, Martijn A van Lavieren4, Peter Damman4, Steven A J Chamuleau5, Michiel Voskuil5, Hein J Verberne6, José P S Henriques4, Berthe L F van Eck-Smit6, Karel T Koch4, Robbert J de Winter4, Jos A E Spaan2, Maria Siebes2, Jan G P Tijssen4, Martijn Meuwissen7, Jan J Piek4.   

Abstract

BACKGROUND: Fractional flow reserve (FFR) aims to identify the extent of epicardial disease, but may be obscured by involvement of the coronary microvasculature. We documented the impact of hyperaemic stenosis resistance (HSR) and hyperaemic microvascular resistance (HMR) on FFR, and its relationship with myocardial ischaemia in patients with stable coronary artery disease. METHODS AND
RESULTS: We evaluated 255 coronary arteries with stenoses of intermediate severity by means of intracoronary pressure and flow measurements to determine FFR, HSR and HMR. Myocardial perfusion scintigraphy (MPS) was performed to identify inducible myocardial ischaemia. In 178 patients, HMR was additionally determined in a reference coronary artery. Target vessel HMR was stratified according to reference vessel HMR tertiles. The diagnostic OR for inducible ischaemia on MPS of a positive compared with a negative FFR was significantly higher only in the presence of a high HMR (at the 0.75 and 0.80 FFR cut-off). Among stenoses with a positive FFR, the prevalence of ischaemia was significantly higher when HMR was high despite equivalent FFR across the HMR groups. This was paralleled by a concomitant significant increase in HSR with increasing HMR across groups. The relation between FFR and HSR (r(2)=0.54, p<0.001) was modulated by the magnitude of HMR, and improved substantially after adjustment for HMR (adjusted-r(2)=0.73, p<0.001), where, for epicardial disease of equivalent severity, FFR increased with increasing HMR.
CONCLUSIONS: Identification of epicardial disease severity by FFR is partly obscured by the microvascular resistance, which illustrates the necessity of combined pressure and flow measurements in daily practice. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24727867     DOI: 10.1136/heartjnl-2013-305124

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  27 in total

Review 1.  Physiologic Assessment of Coronary Stenosis: Current Status and Future Directions.

Authors:  Sercan Okutucu; Mehmet Cilingiroglu; Marc D Feldman
Journal:  Curr Cardiol Rep       Date:  2021-06-03       Impact factor: 2.931

2.  Association of quantitative flow ratio-derived microcirculatory indices with anatomical-functional discordance in intermediate coronary lesions.

Authors:  Liang Geng; Yuan Yuan; Peizhao Du; Liming Gao; Yunkai Wang; Jiming Li; Wei Guo; Ying Huang; Qi Zhang
Journal:  Int J Cardiovasc Imaging       Date:  2021-05-31       Impact factor: 2.357

Review 3.  Assessing the Haemodynamic Impact of Coronary Artery Stenoses: Intracoronary Flow Versus Pressure Measurements.

Authors:  Valérie E Stegehuis; Gilbert Wm Wijntjens; Tadashi Murai; Jan J Piek; Tim P van de Hoef
Journal:  Eur Cardiol       Date:  2018-08

Review 4.  Non-hyperaemic coronary pressure measurements to guide coronary interventions.

Authors:  Tim P van de Hoef; Joo Myung Lee; Mauro Echavarria-Pinto; Bon-Kwon Koo; Hitoshi Matsuo; Manesh R Patel; Justin E Davies; Javier Escaned; Jan J Piek
Journal:  Nat Rev Cardiol       Date:  2020-05-14       Impact factor: 32.419

Review 5.  Fractional flow reserve to guide surgical coronary revascularization.

Authors:  Tara Shah; Joshua D Geleris; Ming Zhong; Rajesh V Swaminathan; Luke K Kim; Dmitriy N Feldman
Journal:  J Thorac Dis       Date:  2017-04       Impact factor: 2.895

6.  Clinical implication of QFR in patients with ST-segment elevation myocardial infarction after drug-eluting stent implantation.

Authors:  Jiani Tang; Jiapeng Chu; Hanjing Hou; Yan Lai; Shengxian Tu; Fei Chen; Yian Yao; Zi Ye; Yanhua Gao; Yu Mao; Shaowei Zhuang; Xuebo Liu
Journal:  Int J Cardiovasc Imaging       Date:  2020-10-12       Impact factor: 2.357

7.  Myocardial blood flow reserve assessed by positron emission tomography myocardial perfusion imaging identifies patients with a survival benefit from early revascularization.

Authors:  Krishna K Patel; John A Spertus; Paul S Chan; Brett W Sperry; Firas Al Badarin; Kevin F Kennedy; Randall C Thompson; James A Case; A Iain McGhie; Timothy M Bateman
Journal:  Eur Heart J       Date:  2020-02-01       Impact factor: 29.983

8.  Physiologic assessment of moderate coronary lesions: a step towards complete revascularization in coronary artery bypass grafting.

Authors:  John C Moscona; Jason D Stencel; Gregory Milligan; Christopher Salmon; Rohit Maini; Paul Katigbak; Qusai Saleh; Ryan Nelson; Sudesh Srivastav; Owen Mogabgab; Rohan Samson; Thierry Le Jemtel
Journal:  Ann Transl Med       Date:  2018-08

Review 9.  Invasive Diagnosis of Coronary Functional Disorders Causing Angina Pectoris.

Authors:  Sascha Beck; Valeria Martínez Pereyra; Andreas Seitz; Johanna McChord; Astrid Hubert; Raffi Bekeredjian; Udo Sechtem; Peter Ong
Journal:  Eur Cardiol       Date:  2021-07-05

10.  The impact of coronary revascularization on vessel-specific coronary flow capacity and long-term outcomes: a serial [15O]H2O positron emission tomography perfusion imaging study.

Authors:  Ruben W de Winter; Ruurt A Jukema; Pepijn A van Diemen; Stefan P Schumacher; Roel S Driessen; Wynand J Stuijfzand; Henk Everaars; Michiel J Bom; Albert C van Rossum; Peter M van de Ven; Niels J Verouden; Alexander Nap; Pieter G Raijmakers; Ibrahim Danad; Paul Knaapen
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2022-06-01       Impact factor: 9.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.